ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Report

Patient Age/Gender: Unknown

Specimen Collected: 09-Dec-20 13:43

X-RUNX1-RUNX1T1 (AML1-ETO) Quantitative **|Received: 09-Dec-20 13:43** **Report/Verified: 09-Dec-20 13:49**

	Result	Units	Reference Interval
RUNX1-RUNX1T1 Source	Whole Blood		
RUNX1-RUNX1T1 Result	Detected [f1 i1]		
RUNX1-RUNX1T1/ABL1 Ratio	1.00000		

Result Footnote

f1: RUNX1-RUNX1T1 Result

RUNX1-RUNX1T1 (AML1-ETO) fusion transcripts were detected by RT-qPCR. This indicates the presence of t(8;21) positive cells in the sample.

This result has been reviewed and approved by Kristin Karner, M.D.

Test Information

i1: RUNX1-RUNX1T1 Result

INTERPRETIVE INFORMATION: RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Quantitative

This test is designed to detect and quantify RUNX1-RUNX1T1 (AML1-ETO) fusion transcripts which result from t(8;21);RUNX1-RUNX1T1, a recurrent genetic abnormality found in a subset of patients with acute myeloid leukemia.

Methodology:
Patient RNA is isolated, reverse transcribed into cDNA, and amplified using primers specific for the RUNX1 and RUNX1T1 genes. Each PCR assay includes a standard curve for RUNX1-RUNX1T1 and the ABL1 control and a normalized copy number (NCN) is calculated (#RUNX1-RUNX1T1 cDNA molecules/# ABL1 cDNA molecules).

Limitations:
Translocations involving other genes or gene partners will not be detected.
Limit of detection for this test is 1 in 100,000.

Results of this test must always be interpreted within the patient's clinical context and in conjunction with other relevant data. Results should not be used alone for a diagnosis of malignancy.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS